Nordic Bioscience, Herlev, Denmark
Institute of Molecular Medicine, Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.
Diabetes Care. 2018 Jul;41(7):1493-1500. doi: 10.2337/dc17-2392. Epub 2018 Apr 11.
Type 2 diabetes is a common risk factor for the development of chronic kidney disease (CKD). Enhanced de novo collagen type VI (COL VI) formation has been associated with renal fibrosis and CKD. We investigated the hypothesis that PRO-C6, a product specifically generated during COL VI formation, is prognostic for adverse outcomes in patients with type 2 diabetes and microalbuminuria.
In a prospective, observational study, we measured PRO-C6 in the serum (S-PRO-C6) and urine (U-PRO-C6) of 198 patients with type 2 diabetes and microalbuminuria without symptoms of coronary artery disease. Patients were followed for a median of 6.5 years, and end points were a composite of cardiovascular events ( = 38), all-cause mortality ( = 26), and reduction of estimated glomerular filtration rate (eGFR) of >30% (disease progression [ = 42]). Cox models were unadjusted and adjusted for the conventional risk factors of sex, age, BMI, systolic blood pressure, LDL cholesterol, smoking, HbA, plasma creatinine, and urinary albumin excretion rate.
Doubling of S-PRO-C6 increased hazards for cardiovascular events (hazard ratio 3.06 [95% CI 1.31-7.14]), all-cause mortality (6.91 [2.96-16.11]), and disease progression (4.81 [1.92-12.01]). Addition of S-PRO-C6 to a model containing conventional risk factors improved relative integrated discrimination by 22.5% for cardiovascular events ( = 0.02), 76.8% for all-cause mortality ( = 0.002), and 53.3% for disease progression ( = 0.004). U-PRO-C6 was not significantly associated with any of the outcomes.
S-PRO-C6 generated during COL VI formation predicts cardiovascular events, all-cause mortality, and disease progression in patients with type 2 diabetes and microalbuminuria.
2 型糖尿病是慢性肾脏病(CKD)发展的常见危险因素。增强的新型胶原 VI(COL VI)形成与肾纤维化和 CKD 有关。我们研究了假设,即在 2 型糖尿病和微量白蛋白尿患者中,专门在 COL VI 形成过程中产生的 PRO-C6 是不良预后的预测因子。
在一项前瞻性、观察性研究中,我们测量了 198 例 2 型糖尿病和微量白蛋白尿患者血清(S-PRO-C6)和尿液(U-PRO-C6)中的 PRO-C6,这些患者没有冠状动脉疾病的症状。患者中位随访时间为 6.5 年,终点是心血管事件( = 38)、全因死亡率( = 26)和肾小球滤过率(eGFR)下降 >30%的复合终点(疾病进展[ = 42])。Cox 模型未经调整,并根据性别、年龄、BMI、收缩压、LDL 胆固醇、吸烟、HbA、血浆肌酐和尿白蛋白排泄率等常规危险因素进行调整。
S-PRO-C6 加倍增加了心血管事件(危险比 3.06[95%CI 1.31-7.14])、全因死亡率(6.91[2.96-16.11])和疾病进展(4.81[1.92-12.01])的风险。将 S-PRO-C6 添加到包含常规危险因素的模型中,可使心血管事件的相对综合区分度提高 22.5%( = 0.02),全因死亡率提高 76.8%( = 0.002),疾病进展提高 53.3%( = 0.004)。U-PRO-C6 与任何结局均无显著相关性。
在 2 型糖尿病和微量白蛋白尿患者中,COL VI 形成过程中产生的 S-PRO-C6 可预测心血管事件、全因死亡率和疾病进展。